This is a guest post on ISSCR 2013. By Dr. Susan Lim A record 4100 delegates attended the 11th Annual Meeting of the International Society for Stem Cell Research (ISSCR), held at the Convention and Exhibition Center in Boston from 12-15 June 2013. Co-sponsored by the Harvard Stem Cell Institute, the Meeting featured 7 Plenary […]
Delightful overview of ISSCR 2013 by guest blogger Dr. Susan Lim Read More »
Today’s post is an interview I did with Dr. Van Bokkelen covering 10 questions. Dr. Gil Van Bokkelen is Chairman and CEO of Athersys, Inc., a company that has focused heavily on stem cells and regenerative medicine for more than a decade. For more on Dr. Van Bokkelen’s background see additional bio section at the end of
Interview with Gil Van Bokkelen of Athersys Read More »
Back-to-back papers (here and here) in Nature Biotechnology report the transdifferentiation (now often simply referred to as “direct reprogramming”) of plain old fibroblasts into brain cells called oligodendrocyte progenitor cells (OPCs). OPCs are a remarkably useful kind of brain cell that generates myelin, which insulates nerves. OPCs are thought to have great therapeutic potential for
Today the Supreme Court agreed to review three cases, none of which were Sherley v Sebelius. What a great day! For those curious, Certiorari Granted (subheading on Supreme Court announcement) means the Court has granted review of these cases. This is wonderful news for patients, the stem cell field, and probably biotech Advanced Cell Technology
Great news as Sherley v Sebelius officially over: Supreme Court Takes a pass Read More »
What are Conflict of Interests (COI)? The term COI is sometimes used inappropriately as a weapon by one party to attempt to discredit others. We see this more and more frequently in the stem cell field with boosters of for-profit, non-FDA vetted adult stem cell clinics attacking scientists for supposed COIs for what…..apparently for simply
Real and imaginary conflicts of interest: a helpful guide Read More »
Who reads this blog? A bunch of cool people including in science, educators, reporters, and patient advocates around the world. Some of them contact me, almost always to say nice things. Sometimes not so nice. To my knowledge this blog remains the only one in the world on stem cells written by a faculty level
The Niche deconstructed: some surprises Read More »
About two months about Geron shocked and disappointed the stem cell community by dropping its stem cell program. The move was reportedly made for financial, not scientific reasons. Biotech companies have to be financially sound in order to help stem cell researchers turn science into cures and Geron’s leadership had to do what it thought
What does Geron’s departure mean for ACT? Some perspectives Read More »
The grapevine is afire with the Geron news and there are many interpretations out there of what it means and why it happened. Based on several accounts from folks who remain anonymous, here is the most probable prediction of what happened to lead us to yesterday’s announcement. Geron has been worried for a long time
The Scarlett letter? What the experts really think about Geron Read More »
Reportedly, Geron has decided to only focus on cancer research and for financial reasons has shut down its hESC trial for spinal cord injury. This is a very sad day for stem cell science. (Update in 2020: the firm still exists, but is working in different areas. The stock has struggled.) No more spinal cord
Bad news as Geron to quit hESC SCI trial for financial reasons Read More »
As much as so many were excited yesterday about the enrollment of the first patient in a CIRM-funded clinical trial, I did not see a mention of a very important element. The patient. Our excitement about the clinical trial moving forward is understandable, but we also need to keep a sober perspective on the fact
The news of CIRM and clinical trial: don’t forget the patient Read More »